EXEL 10 Year Annualized Return and Average Annual Return

The EXEL 10 year annualized return is 25.32% with dividends reinvested through 05/08/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows EXEL average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
EXEL Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into EXEL

Also see:
• EXEL stock yearly return 2016
• EXEL stock yearly return 2017
• EXEL stock yearly return 2018
• EXEL stock yearly return 2019
• EXEL stock yearly return 2020
• EXEL stock yearly return 2021
• EXEL stock yearly return 2022
• EXEL stock yearly return 2023
• EXEL stock yearly return 2024
• EXEL stock yearly return 2025
• EXEL YTD return
Average Annual Return Benchmarks
Compare EXEL average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
EXEL Share Performance
EXEL Average Annual Return Table 10 Years
Start date: 05/10/2016
End date: 05/08/2026
Start price/share: $5.04
End price/share: $48.16
Dividends collected/share: $0.00
Total return: 855.56%
EXEL Average Annual Return: 25.32%
Starting investment: $10,000.00
Ending investment: $95,544.10
Years: 10.00


EXEL average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Exelixis Inc
Exelixis, Inc. is an oncology company. Co. is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The EXEL average annual return 10 years is shown above.

The Average Annual Return on the EXEL average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether EXEL average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the EXEL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
EXEL Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree EXEL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Exelixis (EXEL) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

EYE Average Annual Return
EYEG Average Annual Return
EYES Average Annual Return
EYPT Average Annual Return
FATE Average Annual Return
FBIO Average Annual Return
FBLG Average Annual Return
FBRX Average Annual Return
FDMT Average Annual Return
FEMY Average Annual Return
More Healthcare companies »
★★★★★ Based on a ranking of our entire coverage universe by highest ten year average annual return, Exelixis (EXEL) ranks in the top 25% of all stocks whose returns we have reviewed.
What has the average annual return been for EXEL over the past ten years?
✔️Accepted answer: The ten year EXEL average annual return has been 25.32%.

What start date was used in your EXEL average annual return calculation?
✔️Accepted answer: The start date was 05/10/2016.

What end date was used in your EXEL average annual return calculation?
✔️Accepted answer: The end date was 05/08/2026.

If I had invested $10,000 into EXEL ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 05/08/2026, you would have $95,544.10.

What does that work out to on a total return basis?
✔️Accepted answer: The EXEL ten year total return ending 05/08/2026 works out to 855.56%.


Also see:
• EXEL stock yearly return 2016
• EXEL stock yearly return 2017
• EXEL stock yearly return 2018
• EXEL stock yearly return 2019
• EXEL stock yearly return 2020
• EXEL stock yearly return 2021
• EXEL stock yearly return 2022
• EXEL stock yearly return 2023
• EXEL stock yearly return 2024
• EXEL stock yearly return 2025
• EXEL YTD return
 

EXEL 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.